Newsletter 40/2025
/0 Comments/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! A quick note from me: our newsletter runs on Kit.com, which costs $290/year to keep going. If you enjoy these updates and would like to chip in to help cover the renewal, you can do so here, or send me a […]
Optimized Epigenetic Regulators for Durable Gene Silencing (PCSK9)
/0 Comments/in Preclinical Research/by MaxEfficacy and Safety of Combination ARSI, Denosumab, and Local Radiotherapy in Poly-Metastatic Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxDOLPHIN AI Uncovers Hundreds of Invisible Cancer Markers
/0 Comments/in Artificial Intelligence/by MaxBlocking Ant2 Supercharges the Immune System Against Cancer
/0 Comments/in Immunotherapy, Preclinical Research/by MaxPAM50 Subtyping Identifies Patients With Prostate Cancer Most Likely to Benefit From Apalutamide
/0 Comments/in Clinical Trial, Non-Metastatic, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare alphafold antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Phase 1 Trial: 161Tb-PSMA Offers Hope After Lutetium Failure in mCRPC October 6, 2025
- Newsletter 40/2025 October 5, 2025
- Optimized Epigenetic Regulators for Durable Gene Silencing (PCSK9) October 4, 2025
- Efficacy and Safety of Combination ARSI, Denosumab, and Local Radiotherapy in Poly-Metastatic Prostate Cancer October 4, 2025